Abstract
In order to study efficiency of L-ornithine-L-aspartate (Gepatox) to treat alcoholic liver disease, 32 patients from «Nadiia» clinic and Kyiv Municipal Psychiatry Clinic were chosen and included into two groups. The first main group was treated with basic therapy and Gepatox 10 g i/v. The second control group received basic therapy only. In 5 days the main group showed a significant decrease of ALT, AST and bilirubin in the course of the treatment with Gepatox. The use of Gepatox within the complex treatment of alcoholic liver disease helps not only restore the liver function, but it also improves the patient’s cognitive function which results in better quality of life.
References
Global Status Report on Alcohol and Health, 2018. Режим доступу: https://www.who.int/news-room/fact-sheets/detail/alcohol
Lieber CS. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J Hepatol. 2000;32(1):113-28. doi: 10.1016/s0168-8278(00)80420-1
Singal AK and Anand BS. Recent trends in the epidemiology of alcoholic liver disease. Clin Liver Dis (Hoboken). 2013 Apr;2(2):53-56.
Zhanxiang Zhou. A critical involvement of oxidative stress in acute alcohol-induced hepatic TNF-alpha production. Am J Pathol. 2003 Sep;163(3):1137-46. doi: 10.1016/s0002-9440(10)63473-6.
Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997 Jan;25(1):108-11. doi: 10.1002/hep.510250120.
Ливзан МА, Лялюкова ЕА. Алкогольная болезнь печени: современные аспекты диагностики и лечения. Режим доступу: https://remedium.ru/doctor/gastroenterology/detail.php? ID=68160
Cederbaum AI. Alcohol metabolism. Clin Liver Dis. 2012;16(4):667-685.
Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol. 2004;34(1):9-19.
Luis Pérez Hernández José, Higuera de la Tijera Fátima, Elizabeth Serralde-Zúñiga Aurora, Miguel Abdo Francis Juan. Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure. Annals of Hepatology. 2011;10(2):66-69.
Butterworth RF. Hepatic Encephalopathy — A Serious Complication of Alcoholic. Liver Disease Alcohol Research & Health. 2003;27(2):143-145.
Уніфікований клінічний протокол первинної, вторинної (спеціалізованої) медичної допомоги: АЛКОГОЛЬНИЙ ГЕПАТИТ.
Инструкция к препарату Гепатокс. Режим доступу: http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlz1?opendocument&stype=FC9F4F9352E401EFC225866500346C9C
Najmi AK, Pillai KK, Pal SN, Akhtar M, PAqilal M, Sharma M. Effect of l-ornithine l-aspartate against thioacetamide-induced hepatic damage in rats. Ind J Pharmacol. 2010;42:384-387. doi: 10.4103/0253-7613.71926.
Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmüller E, Holm E. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol. 1993;19:424-430. doi: 10.1016/S0168-8278(05)80553-7.
Fialla AD, Israelsen M, Hamberg O. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis. Liver Int. 2015;35(9):2072-2078. doi: 10.1111/liv.12798.
Kim DK, Kim YH, Jang HH. Estrogen-related receptor γ controls hepatic CB1 receptor-mediated CYP2E1 expression and oxidative liver injury by alcohol. Gut. 2013;62(7):1044-1054. doi: 10.1136/gutjnl‑2012-303347.
Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol. 2005 Dec;3(12):1260-8.
Stickel F, Hampe J. Genetic determinants of alcoholic liver disease. Gut. 2012 Jan;61(1):150-9. doi:10.1136/gutjnl‑2011-301239. Epub 2011 Nov 22.
Farooq MO, Bataller R. Pathogenesis and Management of Alcoholic Liver Disease. https://www.karger.com/Article/Fulltext/444545
Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MТ, Lente FV. Karafa, Frederick Van Lente, Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2003 Feb 15;114(3):188–93. doi: 10.1016/s0002–9343(02)01477–8
Stauch S, Kircheis G, Adler G, Beckh K. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.. J Hepatol. 1998 May;28(5):856-64. https://doi.org/10.1016/s0168-8278(98)80237–7
Gluud LL, Dam G, Les I, Córdoba J, Marchesini G, Borre M, Aagaard NK, Vilstrup H. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2015 Feb;25;(2):CD001939.